Adenosine-mediated inhibition of the cytotoxic activity and cytokine production by activated natural killer cells

Cancer Research

Volumn 66, Issue 15, 2006, Pages 7758-7765

  Lokshin, Anna ^a   Raskovalova, Tatiana ^a   Huang, Xiaojun ^a   Zacharia, Lefteris C ^b   Jackson, Edwin K ^b   Gorelik, Elieser ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 CHLOROADENOSINE; ADENOSINE; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; TUMOR NECROSIS FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXICITY; ENZYME ACTIVE SITE; FEMALE; LYMPHOKINE ACTIVATED KILLER CELL; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL;

2-CHLOROADENOSINE; ADENOSINE; ANIMALS; CYCLIC AMP-DEPENDENT PROTEIN KINASES; CYTOKINES; ENZYME ACTIVATION; FEMALE; ISOENZYMES; KILLER CELLS, LYMPHOKINE-ACTIVATED; MICE; MICE, INBRED C57BL;

EID: 33747873782     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-0478     Document Type: Article

References (41)

1. Burnstock G. The past, present and future of purine nucleotides as signalling molecules. Neuropharmacology 1997;36:1127-39.
2. Klinger M, Freissmuth M, Nanoff C. Adenosine receptors: G protein-mediated signalling and the role of accessory proteins. Cell Signal 2002;14:99-108.
3. Sitkovsky MV, Lukashev D, Apasov S, et al. Physiological control of immune response and inflammatory tissue damage by hypoxia-inducible factors and adenosine A2A receptors. Annu Rev Immunol 2004;22:657-82.
4. Ohta A, Sitkovsky M. Role of G-protein-coupled adenosine receptors in down-regulation of inflammation and protection from tissue damage. Nature 2001;414:916-20.
5. Cronstein BN. Adenosine, an endogenous anti-inflammatory agent. J Appl Physiol 1994;76:5-13.
6. Panther E, Corinti S, Idzko M, et al. Adenosine affects expression of membrane molecules, cytokine and chemokine release, and the T-cell stimulatory capacity of human dendritic cells. Blood 2003;101:3985-90.
7. Szabo C, Scott GS, Virag L, et al. Suppression of macrophage inflammatory protein (MIP)-1α production and collagen-induced arthritis by adenosine receptor agonists. Br J Pharmacol 1998;125:379-87.
8. Lukashev D, Ohta A, Apasov S, Chen JF, Sitkovsky M. Cutting edge: Physiologic attenuation of proinflammatory transcription by the Gs protein-coupled A2A adenosine receptor in vivo. J Immunol 2004;173:21-4.
9. Koshiba M, Kojima H, Huang S, Apasov S, Sitkovsky MV. Memory of extracellular adenosine A2A purinergic receptor-mediated signaling in murine T cells. J Biol Chem 1997;272:25881-9.
10. Huang S, Apasov S, Koshiba M, Sitkovsky M. Role of A2a extracellular adenosine receptor-mediated signaling in adenosine-mediated inhibition of T-cell activation and expansion. Blood 1997;90:1600-10.
11. Hasko G, Kuhel DG, Chen JF, et al. Adenosine inhibits IL-12 and TNF-α production via adenosine A2a receptor-dependent and independent mechanisms. FASEB J 2000;14:2065-74.
12. Blay J, White TD, Hoskin DW. The extracellular fluid of solid carcinomas contains immunosuppressive concentrations of adenosine. Cancer Res 1997;57:2602-5.
13. Raskovalova T, Huang X, Sitkovsky M, Zacharia LC, Jackson EK, Gorelik E. Gs protein-coupled adenosine receptor signaling and lytic function of activated NK cells. J Immunol 2005;175:4383-91.
14. Hoskin DW, Reynolds T, Blay J. 2-Chloroadenosine inhibits the MHC-unrestricted cytolytic activity of anti-CD3-activated killer cells: evidence for the involvement of a non-A1/A2 cell-surface adenosine receptor. Cell Immunol 1994;159:85-93.
15. Hoskin DW, Butler JJ, Drapeau D, Haeryfar SM, Blay J. Adenosine acts through an A3 receptor to prevent the induction of murine anti-CD3-activated killer T cells. Int J Cancer 2002;99:386-95.
16. Chin KV, Yang WL, Ravatn R, et al. Reinventing the wheel of cyclic AMP: novel mechanisms of cAMP signaling. Ann N Y Acad Sci 2002;968:49-64.
17. Skalhegg BS, Tasken K. Specificity in the cAMP/PKA signaling pathway. Differential expression regulation, and subcellular localization of subunits of PKA. Front Biosci 2000;5:D678-93.
18. Cho-Chung YS, Nesterova M, Becker KG, et al. Dissecting the circuitry of protein kinase A and cAMP signaling in cancer genesis: antisense, microarray, gene overexpression, and transcription factor decoy. Ann N Y Acad Sci 2002;968:22-36.
19. Neary CL, Nesterova M, Cho YS, Cheadle C, Becker KG, Cho-Chung YS. Protein kinase A isozyme switching: eliciting differential cAMP signaling and tumor reversion. Oncogene 2004;23:8847-56.
20. Torgersen KM, Vang T, Abrahamsen H, Yaqub S, Tasken K. Molecular mechanisms for protein kinase A-mediated modulation of immune function. Cell Signal 2002;14:1-9.
21. Gunji Y, Vujanovic NL, Hiserodt JC, Herberman RB, Gorelik E. Generation and characterization of purified adherent lymphokine-activated killer cells in mice. J Immunol 1989;142:1748-54.
22. Ortaldo JR, Bere EW, Hodge D, Young HA. Activating Ly-49 NK receptors: central role in cytokine and chemokine production. J Immunol 2001;166:4994-9.
23. Ortaldo JR, Winkler-Pickett R, Wiegand G. Activating Ly-49D NK receptors: expression and function in relation to ontogeny and Ly-49 inhibitor receptors. J Leukoc Biol 2000;68:748-56.
24. Gorelik E, Landsittel DP, Marrangoni AM, et al. Multiplexed immunobead-based cytokine profiling for early detection of ovarian cancer. Cancer Epidemiol Biomarkers Prev 2005;14:981-7.
25. Beebe SJ, Blackmore PF, Chrisman TD, Corbin JD. Use of synergistic pairs of site-selective cAMP analogs in intact cells. Methods Enzymol 1988;159:118-39.
26. Kawasaki H, Springett GM, Mochizuki N, et al. A family of cAMP-binding proteins that directly activate Rap1. Science 1998;282:2275-9.
27. de Rooij J, Zwartkruis FJ, Verheijen MH, et al. Epac is a Rap1 guanine-nucleotide-exchange factor directly activated by cyclic AMP. Nature 1998;396:474-7.
28. Aronoff DM, Canetti C, Serezani CH, Luo M, Peters-Golden M. Cutting edge: macrophage inhibition by cyclic AMP (cAMP): differential roles of protein kinase A and exchange protein directly activated by cAMP-1. J Immunol 2005;174:595-9.
29. Enserink JM, Christensen AE, de Rooij J, et al. A novel Epac-specific CAMP analogue demonstrates independent regulation of Rap1 and ERK. Nat Cell Biol 2002;4:901-6.
30. Mason LH, Anderson SK, Yokoyama WM, Smith HR, Winkler-Pickett R, Ortaldo JR. The Ly-49D receptor activates murine natural killer cells. J Exp Med 1996;184:2119-28.
31. Fischer S, Knoll R, Renz D, Karliczek GF, Schaper W. Role of adenosine in the hypoxic induction of vascular endothelial growth factor in porcine brain derived microvascular endothelial cells. Endothelium 1997;5:155-65.
32. Olah ME, Roudabush FL. Down-regulation of vascular endothelial growth factor expression after A(2A) adenosine receptor activation in PC12 pheochromocytoma cells. J Pharmacol Exp Ther 2000;293:779-87.
33. Leibovich SJ, Chen JF, Pinhal-Enfield G, et al. Synergistic up-regulation of vascular endothelial growth factor expression in murine macrophages by adenosine A(2A) receptor agonists and endotoxin. Am J Pathol 2002;160:2231-44.
34. Davies SP, Reddy H, Caivano M, Cohen P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J 2000;351:95-105.
35. Gjertsen BT, Mellgren G, Otten A, et al. Novel (Rp)-cAMPS analogs as tools for inhibition of cAMP-kinase in cell culture. Basal cAMP-kinase activity modulates interleukin-1β action. J Biol Chem 1995;270:20599-607.
36. Laxminarayana D, Berrada A, Kammer GM. Early events of human T lymphocyte activation are associated with type I protein kinase A activity. J Clin Invest 1993;92:2207-14.
37. Torgersen KM, Vaage JT, Levy FO, Hansson V, Rolstad B, Tasken K. Selective activation of cAMP-dependent protein kinase type I inhibits rat natural killer cell cytotoxicity. J Biol Chem 1997;272:5495-500.
38. Dell'Acqua ML, Scott JD. Protein kinase A anchoring. J Biol Chem 1997;272:12881-4.
39. Bryce PJ, Dascombe MJ, Hutchinson IV. Immunomodulatory effects of pharmacological elevation of cyclic AMP in T lymphocytes proceed via a protein kinase A independent mechanism. Immunopharmacology 1999;41:139-46.
40. Staples KJ, Bergmann M, Tomita K, et al. Adenosine 3′,5′- cyclic monophosphate (cAMP)-dependent inhibition of IL-5 from human T lymphocytes is not mediated by the cAMP-dependent protein kinase A. J Immunol 2001;167:2074-80.
41. Kirschner LS, Kusewitt DF, Matyakhina L, et al. A mouse model for the Carney complex tumor syndrome develops neoplasia in cyclic AMP-responsive tissues. Cancer Res 2005;65:4506-14.